Toluene → 3-((7-(4-chlorophenyl)-3-oxo-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)methyl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide

HRID 2101335

反応式

HRID 2101335 の反応式
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[CH:13]=[CH:12][N:11]3[C:14](=[O:17])[NH:15][N:16]=[C:10]3[C:9]=2[C:18]2[CH:23]=[CH:22][N:21]=[CH:20][CH:19]=2)=[CH:4][CH:3]=1.O[CH2:25][C:26]1[C:27]([CH3:37])=[N+:28]([O-:36])[C:29]([C:32]([F:35])([F:34])[F:33])=[CH:30][CH:31]=1.C1C=CC(P(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.CCOC(/N=N/C(OCC)=O)=O.C1(C)C=CC=CC=1>C1COCC1.CCOC(C)=O>[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[CH:13]=[CH:12][N:11]3[C:14](=[O:17])[N:15]([CH2:25][C:26]4[C:27]([CH3:37])=[N+:28]([O-:36])[C:29]([C:32]([F:35])([F:33])[F:34])=[CH:30][CH:31]=4)[N:16]=[C:10]3[C:9]=2[C:18]2[CH:19]=[CH:20][N:21]=[CH:22][CH:23]=2)=[CH:4][CH:3]=1

参加物

8

反応物 5

HCID 1140TolueneHCID 11776TriphenylphosphineHCID 5462977Diethyl azodicarboxylateHCID 577993927-(4-chlorophenyl)-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-oneHCID 598348163-Pyridinemethanol, 2-methyl-6-(trifluoromethyl)-, 1-oxide

生成物 1

HCID 577993553-((7-(4-chlorophenyl)-3-oxo-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)methyl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide収率 69%

試薬・触媒・溶媒 2

HCID 8028Tetrahydrofuran溶媒HCID 8857Ethyl Acetate溶媒

実験手順

To a suspension of 7-(4-chlorophenyl)-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (64 mg, 0.2 mmol), 3-(hydroxymethyl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide (41 mg, 0.2 mmol) and Ph3P (105 mg, 0.4 mmol) in anhydrous THF (3 mL) at room temperature was added dropwise a 40% solution of DEAD in toluene (0.091 mL, 0.4 mmol). The resulting clear, yellowish solution was then stirred at room temperature for 16 h. The reaction mixture was diluted with EtOAc, washed with saturated aqueous NaHCO3, then saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified using a silica gel cartridge (12 g) eluted with a gradient of ethyl acetate (40-100%) in hexanes to afford 70 mg (69%) of the title compound as a light yellow foam. A portion of the product (10 mg) was further purified using preparative reverse phase HPLC (Phenomenex Luna 5 μm C-18 21.2×100 mm column eluted with a linear gradient of 40% to 80% B over 8 min (A=0.1% trifluoroacetic acid, 90% water, 10% methanol and B=0.1% trifluoroacetic acid, 90% methanol, 10% water) with flow rate at 20 mL/min and UV detection at 220 nm). The desired fractions were concentrated under reduced pressure. The residue was dissolved in EtOAc, washed with saturated aqueous NaHCO3 once, water twice, then saturated aqueous NaCl, dried over Na2SO4 and evaporated. The residue was dissolved in acetonitrile, frozen and lyophilized to afford 7.2 mg of the title compound as a light yellow powder. HPLC/MS: retention time=2.33 min, [M+H]+=512.0.

後処理

  1. washwashed with saturated aqueous NaHCO3
  2. dry with materialsaturated aqueous NaCl, dried (Na2SO4)
  3. filtrationfiltered
  4. concentrationconcentrated under reduced pressure
  5. customThe crude product was purified
  6. washeluted with a gradient of ethyl acetate (40-100%) in hexanes

出典と根拠

ORDレコード
ord-c82b34634b424ae5afd1b1f2a0b6a9d6
出典データセット
uspto-grants-2009_08
特許番号
US07572808B2

関連ノート

読み込み中…